vs
Apellis Pharmaceuticals, Inc.（APLS）与STURM RUGER & CO INC（RGR）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是STURM RUGER & CO INC的1.3倍（$199.9M vs $151.1M），STURM RUGER & CO INC同比增速更快（3.6% vs -5.9%），STURM RUGER & CO INC自由现金流更多（$12.3M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 5.1%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
鲁格公司（Ruger）是总部位于美国康涅狄格州绍斯波特的枪械制造企业，除总部外，还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立，自1969年起公开上市交易。
APLS vs RGR — 直观对比
营收规模更大
APLS
是对方的1.3倍
$151.1M
营收增速更快
RGR
高出9.6%
-5.9%
自由现金流更多
RGR
多$26.6M
$-14.3M
两年增速更快
APLS
近两年复合增速
5.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $151.1M |
| 净利润 | $-59.0M | — |
| 毛利率 | — | 17.8% |
| 营业利润率 | -25.6% | 2.3% |
| 净利率 | -29.5% | — |
| 营收同比 | -5.9% | 3.6% |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSRGR
| Q4 25 | $199.9M | $151.1M | ||
| Q3 25 | $458.6M | $126.8M | ||
| Q2 25 | $178.5M | $132.5M | ||
| Q1 25 | $166.8M | $135.7M | ||
| Q4 24 | $212.5M | $145.8M | ||
| Q3 24 | $196.8M | $122.3M | ||
| Q2 24 | $199.7M | $130.8M | ||
| Q1 24 | $172.3M | $136.8M |
净利润APLSRGR
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $1.6M | ||
| Q2 25 | $-42.2M | $-17.2M | ||
| Q1 25 | $-92.2M | $7.8M | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-57.4M | $4.7M | ||
| Q2 24 | $-37.7M | $8.3M | ||
| Q1 24 | $-66.4M | $7.1M |
毛利率APLSRGR
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | 15.1% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | — | 22.0% | ||
| Q4 24 | — | 22.8% | ||
| Q3 24 | — | 18.5% | ||
| Q2 24 | — | 22.3% | ||
| Q1 24 | — | 21.5% |
营业利润率APLSRGR
| Q4 25 | -25.6% | 2.3% | ||
| Q3 25 | 48.7% | -2.7% | ||
| Q2 25 | -18.6% | -15.6% | ||
| Q1 25 | -50.0% | 6.2% | ||
| Q4 24 | -12.3% | 7.8% | ||
| Q3 24 | -24.0% | 3.1% | ||
| Q2 24 | -14.7% | 6.9% | ||
| Q1 24 | -36.0% | 5.5% |
净利率APLSRGR
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | 1.2% | ||
| Q2 25 | -23.6% | -13.0% | ||
| Q1 25 | -55.3% | 5.7% | ||
| Q4 24 | -17.1% | — | ||
| Q3 24 | -29.2% | 3.9% | ||
| Q2 24 | -18.9% | 6.3% | ||
| Q1 24 | -38.5% | 5.2% |
每股收益（稀释后）APLSRGR
| Q4 25 | $-0.40 | $0.22 | ||
| Q3 25 | $1.67 | $0.10 | ||
| Q2 25 | $-0.33 | $-1.05 | ||
| Q1 25 | $-0.74 | $0.46 | ||
| Q4 24 | $-0.30 | $0.62 | ||
| Q3 24 | $-0.46 | $0.28 | ||
| Q2 24 | $-0.30 | $0.47 | ||
| Q1 24 | $-0.54 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $92.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $283.8M |
| 总资产 | $1.1B | $342.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSRGR
| Q4 25 | $466.2M | $92.5M | ||
| Q3 25 | $479.2M | $80.8M | ||
| Q2 25 | $370.0M | $101.4M | ||
| Q1 25 | $358.4M | $108.3M | ||
| Q4 24 | $411.3M | $105.5M | ||
| Q3 24 | $396.9M | $96.0M | ||
| Q2 24 | $360.1M | $105.6M | ||
| Q1 24 | $325.9M | $115.3M |
总债务APLSRGR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSRGR
| Q4 25 | $370.1M | $283.8M | ||
| Q3 25 | $401.2M | $279.6M | ||
| Q2 25 | $156.3M | $289.3M | ||
| Q1 25 | $164.2M | $321.5M | ||
| Q4 24 | $228.5M | $319.6M | ||
| Q3 24 | $237.1M | $314.9M | ||
| Q2 24 | $264.3M | $321.5M | ||
| Q1 24 | $266.7M | $332.0M |
总资产APLSRGR
| Q4 25 | $1.1B | $342.0M | ||
| Q3 25 | $1.1B | $342.3M | ||
| Q2 25 | $821.4M | $349.5M | ||
| Q1 25 | $807.3M | $379.0M | ||
| Q4 24 | $885.1M | $384.0M | ||
| Q3 24 | $901.9M | $373.5M | ||
| Q2 24 | $904.5M | $376.7M | ||
| Q1 24 | $831.9M | $385.0M |
负债/权益比APLSRGR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $12.3M |
| 自由现金流率自由现金流/营收 | -7.1% | 8.2% |
| 资本支出强度资本支出/营收 | 0.1% | 2.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $38.5M |
8季度趋势，按日历期对齐
经营现金流APLSRGR
| Q4 25 | $-14.2M | $15.5M | ||
| Q3 25 | $108.5M | $12.9M | ||
| Q2 25 | $4.4M | $14.7M | ||
| Q1 25 | $-53.4M | $11.1M | ||
| Q4 24 | $19.4M | $20.0M | ||
| Q3 24 | $34.1M | $9.4M | ||
| Q2 24 | $-8.3M | $18.7M | ||
| Q1 24 | $-133.0M | $7.3M |
自由现金流APLSRGR
| Q4 25 | $-14.3M | $12.3M | ||
| Q3 25 | $108.3M | $7.0M | ||
| Q2 25 | $4.4M | $9.1M | ||
| Q1 25 | $-53.4M | $10.0M | ||
| Q4 24 | $19.3M | $16.4M | ||
| Q3 24 | — | $2.6M | ||
| Q2 24 | $-8.4M | $10.1M | ||
| Q1 24 | $-133.3M | $5.6M |
自由现金流率APLSRGR
| Q4 25 | -7.1% | 8.2% | ||
| Q3 25 | 23.6% | 5.5% | ||
| Q2 25 | 2.5% | 6.9% | ||
| Q1 25 | -32.0% | 7.4% | ||
| Q4 24 | 9.1% | 11.2% | ||
| Q3 24 | — | 2.1% | ||
| Q2 24 | -4.2% | 7.7% | ||
| Q1 24 | -77.3% | 4.1% |
资本支出强度APLSRGR
| Q4 25 | 0.1% | 2.1% | ||
| Q3 25 | 0.0% | 4.6% | ||
| Q2 25 | 0.0% | 4.2% | ||
| Q1 25 | 0.0% | 0.8% | ||
| Q4 24 | 0.0% | 2.5% | ||
| Q3 24 | 0.0% | 5.5% | ||
| Q2 24 | 0.0% | 6.6% | ||
| Q1 24 | 0.2% | 1.3% |
现金转化率APLSRGR
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 8.15× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 2.27× | ||
| Q1 24 | — | 1.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
